COVID-19 and Treatment and Immunization of Children—The Time to Redefine Pediatric Age Groups is Here
| Autor: | Pasquale Striano, Klaus Rose, David Neubauer, Oishi Tanjinatus, Jane M. Grant-Kels, Earl B. Ettienne |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Medicine (General)
Pediatrics medicine.medical_specialty Coronavirus disease 2019 (COVID-19) pediatric drug development Biological age MEDLINE Review Article Better medicines for children R5-920 Pandemic medicine Drug approval pediatric legislation media_common.cataloged_instance European union children as therapeutic orphans media_common Children as therapeutic orphans COVID-19 Developmental pharmacology Pediatric drug development Pediatric legislation business.industry Pediatric age General Medicine Immunization Medicine developmental pharmacology business |
| Zdroj: | Rambam Maimonides Medical Journal Rambam Maimonides Medical Journal, Vol 12, Iss 2, p e0010 (2021) |
| ISSN: | 2076-9172 |
| DOI: | 10.5041/rmmj.10433 |
| Popis: | Children are infected with coronavirus disease 2019 (COVID-19) as often as adults, but with fewer symptoms. During the first wave of the COVID-19 pandemic, multisystem inflammatory syndrome (MIS) in children (MIS-C), with symptoms similar to Kawasaki syndrome, was described in young minors testing positive for COVID-19. The United States (US) Centers for Disease Control and Prevention (CDC) defined MIS-C as occurring in |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|